In conclusion, through a combination of in vitro assays and in vivo methods, we elucidated that HOXC-AS3 promotes NSCLC progression by stabilising YBX1 expression and thus enhancing HOXC8 transcription. This evidence concerns the gene YBX1 and non-small cell lung carcinoma.